NCT06689345

Brief Summary

The aim of this study is to analyse whether there is an advantage in adding low-intensity electrical stimulations to the vagus nerve with electrodes in the outer ear to control pain and fatigue in people with primary chronic pain, and in people who have had COVID-19. Several studies have shown that many people with primary chronic pain and also people who have had COVID patients continue to have pain and fatigue that may be due to changes that occur in the brain and the vagus nerve that passes through the neck might cause inflammation. Therefore the aim of this study is to investigate if these electrical stimulations can help improve the condition of the brain and nerve and consequently, the inflammation so that these complaints improve. This study will be organized as the following: It will begin with an assessment, divided into a part with questionnaires and another with specific tests. The questionnaires are aimed at understanding volunteer's characteristics, pain, fatigue, inflammation, sleep, quality of life, and the presence of symptoms of anxiety and depression. Next, the volunteer will undergo two tests to assess the behavior of his/her brain. They are performed using EEG electroencephalography and transcranial magnetic stimulation (TMS).

  • Quantitative EEG at rest - In this technique, a cap with electrodes is placed on volunteer's head, in contact with hair, which are connected through a gel. The volunteer needs to remain still for 6 minutes with eyes closed, sitting in a comfortable chair.
  • TMS with EEG - First, the volunteer will be asked to honestly answer the questions in the safety questionnaire for using this technique. Honest answers will eliminate the risks associated with this evaluation. Next, the volunteer's skin will be cleaned with alcohol and a special paste and place three self-adhesive electrodes on the muscle of the volunteer's hand, in a muscle called the interosseous, on the side where he/she writes. These electrodes will only capture the electrical activity of the muscle. Next, a series of magnetic pulses will be administered to the volunteer's skull, in the area that controls the hand muscle. It will contract with each pulse and, with this, so that the functioning of this connection can be understood. At the same time, the EEG device will capture the brain activities that occur during this TMS stimulation. During this exam, the volunteer may feel anything from no stimulation to muscle contractions that move his/her hand. Some people also experience redness under the electrodes, fatigue, or muscle/joint pain. After the assessments, volunteers will be randomly selected to receive neuromodulation sessions using low-intensity electrical stimulation of the vagus nerve, using electrodes in the outer ear (active group), or sessions that only simulate this neuromodulation (sham, or placebo, group). This will occur for five consecutive days, starting on the day of the assessment. This stimulation is very weak and may not even be felt by the person receiving it. This technique is safe and the most that may occur is redness or itching of the skin. A few people may also experience tingling, a burning sensation or momentary local pain, fatigue, drowsiness, difficulty concentrating and a feeling of nervousness during or after the stimulation. At the end of the 5 days of electrical stimulation, the same initial assessments will be repeated to see if anything has changed in the volunteer's brain, heart rate, blood pressure, pain, fatigue, inflammation, sleep, quality of life, depression, and anxiety.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 21, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 27, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 14, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 16, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2024

Completed
Last Updated

November 14, 2024

Status Verified

September 1, 2024

Enrollment Period

8 months

First QC Date

September 27, 2024

Last Update Submit

November 13, 2024

Conditions

Keywords

neuromodulationchronic paincovid-19TMS-EEGvagal nerve

Outcome Measures

Primary Outcomes (1)

  • Pain

    It will be assessed through the Brief Pain Inventory (BPI), that assess place and pain intensity and its impact in life and by multidimensional pain assessment instruments to evaluate pain experience and self-efficacy

    5 days

Secondary Outcomes (4)

  • Heart rate variability and blood preasure

    5 days

  • Pressure pain threshold.

    5 days

  • TMS-Evoked potential

    5 days

  • Disautonomy, fatigue and mental health

    5 days

Study Arms (3)

Healthy subjects

OTHER

Once a week, each subject will receive a random stimulation in one of the following areas: (i) the afferent portion of the vagal nerve on the Cymba Conchae of the left ear (taVNS); (ii) rPMS on an efferent portion of the vagal nerve on the neck; (iii) rTMS intermittent theta- burst on the left DLPFC; (iv) simulated taVNS (SHAM) on helix left ear or.

Device: taVNS - transauricular vagal nerve stimulationDevice: rPMS - repetitive peripheric magnetic stimulationDevice: rTMS - repetitive transcranial magnetic stimulationDevice: taVNS sham

Chronic Pain and post Covid Syndrom - Active

EXPERIMENTAL

These volunteers will receive 30 minutes of taVNS on the afferent portion of the vagal nerve on the ears.

Device: taVNS - transauricular vagal nerve stimulation

Chronic Pain and post Covid Syndrom - Sham

SHAM COMPARATOR

These volunteers will receive 30 minutes of simulated taVNS on the afferent portion of the vagal nerve on the ears. For this, the equipment will be programmed to be on only for 1 minute.

Device: taVNS sham

Interventions

30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.

Chronic Pain and post Covid Syndrom - ActiveHealthy subjects

Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).

Healthy subjects

rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.

Healthy subjects

Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute

Chronic Pain and post Covid Syndrom - ShamHealthy subjects

Eligibility Criteria

Age18 Years - 64 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy individuals, both sexes, aged between 18 and 40 years (first arm).
  • Diagnosis of primary chronic pain (for more than 3 months), such as fibromyalgia (chronic widespread pain), primary chronic headache and orofacial pain, chronic primary visceral pain, post-COVID pain, and chronic primary musculoskeletal pain;
  • In the case of post-COVID-19 pain, the symptoms must be present for at least 12 weeks. The complaints of pain, fatigue, and/or changes in mental health should have started after infection by SARS-Cov-2.

You may not qualify if:

  • Individuals who present dysautonomia;
  • obese individuals with a high abdominal fat index characterized by a waist/hip ratio of 0.80 for women and 0.95 for men;
  • heart disease;
  • diabetes mellitus;
  • vestibular alterations characterized by the Dix-Hallpike maneuver, supine rotation test, arc test, side-lying maneuver, and post-head-shake nystagmus;
  • diagnosis of epilepsy or first-degree family history of epilepsy
  • fever;
  • chronic consumption of alcohol, or other recreational drugs;
  • presence of contraindications for the use of non-invasive neuromodulation;
  • those who become ill with COVID-19 during the data collection period;
  • those who are unable to answer the evaluation questionnaires;
  • those with clinical instability;
  • those who have a previous history of chronic pain or fatigue before contracting COVID-19;
  • those who have neuropathic pain.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Federal University of ABC

Sâo Bernardo Do Campo, São Paulo, 09606045, Brazil

Location

MeSH Terms

Conditions

Post-Acute COVID-19 SyndromeChronic PainCOVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Tiago S Lopes, PhD

    Federal University of ABC

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Model Details: First, we will test the savety and effects of neuromodulation using four different tecniques on autonomous system of healthy people. Then, we will test the effect of neuromodulation through, vagal stimulation, on pain, fatigue, mental healthy and disautonomy of people with primary chronic pain and/or post-COVID syndrom. For this, active and sham stimulations will be compared.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2024

First Posted

November 14, 2024

Study Start

April 21, 2024

Primary Completion

December 16, 2024

Study Completion

December 16, 2024

Last Updated

November 14, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations